Trial reportCNS drugs2008
Predictors of 12-month outcome in smokers who received bupropion sustained-release for smoking cessation.
Trial report in CNS drugs, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 6 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Differences in the effectiveness of individual-level smoking cessation interventions by socioeconomic status.The Cochrane database of systematic reviews · 2025Pooled it
- Antidepressants for smoking cessation.The Cochrane database of systematic reviews · 2020Pooled it
- Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation.The Cochrane database of systematic reviews · 2019Pooled it
- Telephone counselling for smoking cessation.The Cochrane database of systematic reviews · 2019Pooled it
- Combined pharmacotherapy and behavioural interventions for smoking cessation.The Cochrane database of systematic reviews · 2016Pooled it
- Antidepressants for smoking cessation.The Cochrane database of systematic reviews · 2014Pooled it
- Six Month Abstinence Heterogeneity in the Best Quit Study.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2019Trial
- Predictors of engagement in post-discharge quitline counseling among hospitalized smokers.Journal of behavioral medicine · 2019Trial
- Anhedonia: Its Dynamic Relations With Craving, Negative Affect, and Treatment During a Quit Smoking Attempt.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2017Trial
- Anhedonia as a component of the tobacco withdrawal syndrome.Journal of abnormal psychology · 2015Trial
- Feasibility and acceptability of a multiple risk factor intervention: the Step Up randomized pilot trial.BMC public health · 2011Trial
- Smoking outcome by psychiatric history after behavioral and varenicline treatment.Journal of substance abuse treatment · 2010Trial
- A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies.Archives of general psychiatry · 2009Trial
- Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline.Journal of general internal medicine · 2009Trial
- Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation.Human molecular genetics · 2008Trial
- Antidepressants for smoking cessation.The Cochrane database of systematic reviews · 2023Review
- Sleep Disturbance During Smoking Cessation: Withdrawal or Side Effect of Treatment?Journal of smoking cessation · 2017Article
- Adult Cigarette Smokers at Highest Risk for Concurrent Alternative Tobacco Product Use Among a Racially/Ethnically and Socioeconomically Diverse Sample.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2016Article
- Bumps along the translational pathway: anticipating uptake of tailored smoking cessation treatment.Personalized medicine · 2013Article
- Factors associated with caregiver stability in permanent placements: a classification tree approach.Child abuse & neglect · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
aimTo examine heterogeneity in outcome at 12 months following 8 weeks of treatment for smoking cessation with bupropion sustained-release (SR) 150 or 300 mg/day combined with behavioural counselling. DESIGN, SETTING,
participantsSmokers were recruited from a large healthcare system and then randomized to receive either bupropion SR 150 mg/day (n = 763) or 300 mg/day (n = 761) taken for 8 weeks in combination with either proactive telephone counselling or a tailored mail approach. MEASUREMENTS AND
findingsA comprehensive set of relevant individual pretreatment and treatment characteristics was included in the analysis. Smoking outcome at 12 months was defined as point-prevalence of any regular self-reported smoking within the 7 days prior to follow-up contact. Classification and regression tree analysis identified subgroups that varied with respect to likelihood of being nonsmokers at 12 months. Seven subgroups were identified among those receiving bupropion SR 150 mg/day (proportion of nonsmokers at 12 months ranged from 13.7% to 43.5%) and eight subgroups among those receiving bupropion SR 300 mg/day (proportion of nonsmokers at 12 months ranged from 9.6% to 51.7%). In the 150-mg/day group, those with the lowest rate reported no previous quit attempt of 1 month or more in duration while those with the highest rate all reported previous quit attempts of 1 month or longer. In the 300 mg/day group, those with the lowest rate had very high levels of dependence while those with the highest rate were more highly educated and smoked at a lower level. Across all subgroups, cost per 12-month quitter ranged from a low of USD302 to a high of USD2,502.
conclusionsThese results indicate the presence of a substantial amount of variation in outcome following treatment with both dosages of bupropion SR, with substantial cost consequences. Variation in outcome could be reduced by providing treatments tailored to subgroups of individuals who are at exceptionally high risk for smoking following a quit attempt.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.